| scholarly article | Q13442814 |
| P2093 | author name string | Anja Schmidt | |
| Georg Wensing | |||
| Reiner Frey | |||
| Sigrun Unger | |||
| Wolfgang Mück | |||
| Corina Becker | |||
| P2860 | cites work | Determination of the free fraction and relative free fraction of drugs strongly bound to plasma proteins | Q74039077 |
| CYP1A2 is expressed along with CYP1A1 in the human lung | Q74312378 | ||
| CYP1A1 levels in lung tissue of tobacco smokers and polymorphisms of CYP1A1 and aromatic hydrocarbon receptor | Q74373330 | ||
| Expression of cytochromes P450 1A1 and 1B1 in human lung from smokers, non-smokers, and ex-smokers | Q80557158 | ||
| Worsening renal function and prognosis in pulmonary hypertension patients hospitalized for right heart failure | Q84137797 | ||
| NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential | Q24656131 | ||
| Human Cytochrome P450 1A1 Structure and Utility in Understanding Drug and Xenobiotic Metabolism | Q27676875 | ||
| Prediction of creatinine clearance from serum creatinine | Q29615603 | ||
| Nitric oxide activates guanylate cyclase and increases guanosine 3′:5′-cyclic monophosphate levels in various tissue preparations | Q30449094 | ||
| Riociguat for the treatment of chronic thromboembolic pulmonary hypertension | Q33163081 | ||
| Riociguat for the treatment of pulmonary arterial hypertension | Q33163083 | ||
| Committee for Medicinal Products for Human Use (CHMP) assessment on efficacy of antidepressants | Q33415894 | ||
| Riociguat (BAY 63–2521) and Warfarin: A Pharmacodynamic and Pharmacokinetic Interaction Study | Q33447738 | ||
| Induction of cytochrome P4501A1. | Q33636653 | ||
| Liver cirrhosis | Q34010340 | ||
| Hepatic encephalopathy--definition, nomenclature, diagnosis, and quantification: final report of the working party at the 11th World Congresses of Gastroenterology, Vienna, 1998. | Q34116455 | ||
| Transection of the oesophagus for bleeding oesophageal varices | Q34211834 | ||
| An evaluation of long-term survival from time of diagnosis in pulmonary arterial hypertension from the REVEAL Registry | Q34249972 | ||
| Expression and function of soluble guanylate cyclase in pulmonary arterial hypertension. | Q34786286 | ||
| First acute haemodynamic study of soluble guanylate cyclase stimulator riociguat in pulmonary hypertension | Q34917310 | ||
| Soluble guanylate cyclase as an emerging therapeutic target in cardiopulmonary disease | Q35010064 | ||
| Liver abnormalities in cardiac diseases and heart failure | Q35902564 | ||
| Detection of CYP1A1 protein in human liver and induction by TCDD in precision-cut liver slices incubated in dynamic organ culture | Q41007634 | ||
| Effects of omeprazole and aluminum hydroxide/magnesium hydroxide on riociguat absorption | Q41165804 | ||
| Riociguat (BAY 63-2521) and aspirin: a randomized, pharmacodynamic, and pharmacokinetic interaction study | Q41166010 | ||
| Pharmacokinetic interaction of riociguat with ketoconazole, clarithromycin, and midazolam | Q41166308 | ||
| Riociguat for chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension: a phase II study. | Q42663215 | ||
| Tissue distribution of mRNA expression of human cytochrome P450 isoforms assessed by high-sensitivity real-time reverse transcription PCR. | Q44457201 | ||
| Tobacco smoke-dependent changes in cytochrome P450 1A1, 1A2, and 2E1 protein expressions in fetuses, newborns, pregnant rats, and human placenta | Q45078610 | ||
| No pharmacodynamic (PD) and pharmacokinetic (PK) interaction of riociguat (BAY 63-2521) and aspirin. | Q45928610 | ||
| Single-dose pharmacokinetics, pharmacodynamics, tolerability, and safety of the soluble guanylate cyclase stimulator BAY 63-2521: an ascending-dose study in healthy male volunteers | Q46562534 | ||
| Pharmacokinetics of the soluble guanylate cyclase stimulator riociguat in individuals with hepatic impairment | Q47132669 | ||
| Characterization of microsomal cytochrome P450 enzymes involved in the oxidation of xenobiotic chemicals in human fetal liver and adult lungs. | Q50139180 | ||
| Expression of CYP1A1 gene in patients with lung cancer: evidence for cigarette smoke-induced gene expression in normal lung tissue and for altered gene regulation in primary pulmonary carcinomas. | Q52240442 | ||
| Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. | Q52422731 | ||
| Pulmonary Arterial Hypertension | Q56388760 | ||
| P433 | issue | Suppl 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | riociguat | Q2154494 |
| pharmacokinetics | Q323936 | ||
| P304 | page(s) | S5-S14 | |
| P577 | publication date | 2016-03-01 | |
| P1433 | published in | Pulmonary circulation | Q26842412 |
| P1476 | title | Assessment of the effects of hepatic impairment and smoking on the pharmacokinetics of a single oral dose of the soluble guanylate cyclase stimulator riociguat (BAY 63-2521) | |
| P478 | volume | 6 |
| Q48023226 | Assessment of the pulmonary CYP1A1 metabolism of mavoglurant (AFQ056) in rat. |
| Q47584698 | Clinical Pharmacokinetic and Pharmacodynamic Profile of Riociguat |
| Q47110570 | First-in-child use of the oral soluble guanylate cyclase stimulator riociguat in pulmonary arterial hypertension |
| Q93172741 | Pharmacokinetic interaction of riociguat and antiretroviral combination regimens in HIV-1-infected adults |
| Q36881711 | Population pharmacokinetics of single-dose riociguat in patients with renal or hepatic impairment |
| Q92785757 | Practical management of riociguat in patients with pulmonary arterial hypertension |
| Q53835859 | Riociguat treatment for portopulmonary hypertension: a subgroup analysis from the PATENT-1/-2 studies. |
| Q33596457 | Riociguat: a soluble guanylate cyclase stimulator for the treatment of pulmonary hypertension |
| Q90660734 | Treatment Barriers in Portopulmonary Hypertension |
Search more.